Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC. The presentations will include three posters on STA-9090, a potent inhibitor of Hsp90, which further differentiate the compound from other agents in this class and two posters on elesclomol, a small-molecule oxidative stress inducer, which further elucidate the mechanism of action and guide towards choice of patients for future trials.

“Anticancer activity of elesclomol correlates with low LDH levels and active mitochondrial respiration”

STA-9090 Posters

"Hsp90 inhibitor STA-9090 induces HIF-1α degradation in the hypoxic regions of solid tumors" (abstract #2638) - Apr. 19, 2:00 - 5:00 p.m. ET; Regulation of Protein Stability; Poster Section 26, Board 16.

"Multimodal action of the Hsp90 inhibitor STA-9090 in treating cancer cells with activated JAK/STAT signaling" (abstract #2640) - Apr. 19, 2:00 - 5:00 p.m. ET; Regulation of Protein Stability; Poster Section 26, Board 18.

"Hsp90 inhibitor STA-9090 enhances the activity of standard of care therapies in erlotinib-sensitive and -resistant NSCLC models" (abstract #2637) - Apr. 19, 2:00 - 5:00 p.m. ET; Regulation of Protein Stability; Poster Section 26, Board 15.

Elesclomol Posters

"Anticancer activity of elesclomol correlates with low LDH levels and active mitochondrial respiration" (abstract #4545) - Apr. 20, 2:00 - 5:00 p.m. ET; Tumor Metabolism and Regulation of Apoptosis; Poster Section 26, Board 25.

"Targeting ROS to kill cisplatin-resistant cells" (abstract #4525) - Apr. 20, 2:00 - 5:00 p.m. ET; Tumor Metabolism and Regulation of Apoptosis; Poster Section 26, Board 5.